Zentalis Pharmaceuticals (ZNTL) Profit After Tax (2019 - 2026)

Zentalis Pharmaceuticals' Profit After Tax history runs 8 years deep, the most recent figure standing at -$35.4 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 26.78% year-over-year to -$35.4 million; the TTM figure through Mar 2026 stood at -$124.1 million (up 44.63% YoY), while the FY2025 annual figure was -$137.1 million, up 17.37% from the prior year.
• Profit After Tax was -$35.4 million for Q1 2026 at Zentalis Pharmaceuticals, roughly flat from -$35.2 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $10.1 million in Q1 2024 to a low of -$112.5 million in Q2 2023.
• Historically, Profit After Tax has averaged -$51.0 million across 5 years, with a median of -$54.5 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Profit After Tax plunged 1200.41% in 2022, then surged 115.91% in 2024.
• A 5-year view of Profit After Tax shows it stood at -$54.7 million in 2022, then declined by 11.24% to -$60.8 million in 2023, then grew by 21.95% to -$47.5 million in 2024, then rose by 25.82% to -$35.2 million in 2025, then declined by 0.39% to -$35.4 million in 2026.
• The last three Profit After Tax figures came in at -$35.4 million (Q1 2026), -$35.2 million (Q4 2025), and -$26.7 million (Q3 2025), per Business Quant data.